Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Expanding rare disease drug trials based on shared molecular etiology

Nature Biotechnology volume 32, pages 515–518 (2014)Cite this article

Subjects

Current clinical trial approaches in rare disease test one drug on one indication defined by a clinical phenotype. For targeted drugs, grouping patients by molecular etiology would make much more sense.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Benefits of grouping by molecular etiology.

References

  1. Mort, M., Ivanov, D., Cooper, D.N. & Chuzhanova, N.A. Hum. Mutat. 29, 1037–1047 (2008).

    Article  CAS  Google Scholar 

  2. Peltz, S.W., Morsy, M., Welch, E.M. & Jacobson, A. Annu. Rev. Med. 64, 407–425 (2013).

    Article  CAS  Google Scholar 

  3. Auld, D.S., Thorne, N., Maguire, W.F. & Inglese, J. Proc. Natl. Acad. Sci. USA 106, 3585–3590 (2009).

    Article  CAS  Google Scholar 

  4. McElroy, S.P. et al. PLoS Biol. 11, e1001593 (2013).

    Article  CAS  Google Scholar 

  5. Wilschanski, M. et al. Eur. Respir. J. 38, 59–69 (2011).

    Article  CAS  Google Scholar 

  6. Kuschal, C., Digiovanna, J.J., Khan, S.G., Gatti, R.A. & Kraemer, K.H. Proc. Natl. Acad. Sci. USA 110, 19483–19488 (2013).

    Article  CAS  Google Scholar 

  7. Du, L. et al. J. Exp. Med. 206, 2285–2297 (2009).

    Article  CAS  Google Scholar 

  8. Nudelman, I. et al. J. Med. Chem. 52, 2836–2845 (2009).

    Article  CAS  Google Scholar 

  9. Dietz, H.C. N. Engl. J. Med. 363, 852–863 (2010).

    Article  CAS  Google Scholar 

  10. Linde, L. & Kerem, B. Trends Genet. 24, 552–563 (2008).

    Article  CAS  Google Scholar 

  11. Keeling, K.M. & Bedwell, D.M. Wiley Interdiscip. Rev. RNA 2, 837–852 (2011).

    Article  CAS  Google Scholar 

  12. Kuzmiak, H.A. & Maquat, L.E. Trends Mol. Med. 12, 306–316 (2006).

    Article  CAS  Google Scholar 

  13. Keeling, K.M. et al. PLoS ONE 8, e60478 (2013).

    Article  CAS  Google Scholar 

  14. Lindquist, S.L. & Kelly, J.W. Cold Spring Harb. Perspect. Biol. 3, a004507 (2011).

    Article  Google Scholar 

  15. Amaral, M.D. & Farinha, C.M. Curr. Pharm. Des. 19, 3497–3508 (2013).

    Article  CAS  Google Scholar 

  16. Parenti, G. EMBO Mol. Med. 1, 268–279 (2009).

    Article  CAS  Google Scholar 

  17. Bemporad, F. & Chiti, F. Chem. Biol. 19, 315–327 (2012).

    Article  CAS  Google Scholar 

  18. Balch, W.E., Morimoto, R.I., Dillin, A. & Kelly, J.W. Science 319, 916–919 (2008).

    Article  CAS  Google Scholar 

  19. Wang, F., Song, W., Brancati, G. & Segatori, L. J. Biol. Chem. 286, 43454–43464 (2011).

    Article  CAS  Google Scholar 

  20. Yang, C. et al. Proc. Natl. Acad. Sci. USA 111, 249–254 (2014).

    Article  CAS  Google Scholar 

  21. Mu, T.W., Fowler, D.M. & Kelly, J.W. PLoS Biol. 6, e26 (2008).

    Article  Google Scholar 

  22. Garber, K. Nat. Biotechnol. 31, 189 (2013).

    Article  CAS  Google Scholar 

  23. Quintana-Gallego, E., Delgado-Pecellín, I. & Calero Acuña, C. Arch. Bronconeumol. 50, 146–150 (2014).

    Article  Google Scholar 

  24. Myerowitz, R. Hum. Mutat. 9, 195–208 (1997).

    Article  CAS  Google Scholar 

  25. Hruska, K.S., LaMarca, M.E., Scott, C.R. & Sidransky, E. Hum. Mutat. 29, 567–583 (2008).

    Article  CAS  Google Scholar 

  26. Mossé, Y.P. et al. Lancet Oncol. 14, 472–480 (2013).

    Article  Google Scholar 

  27. Pichavant, C. et al. Mol. Ther. 19, 830–840 (2011).

    Article  CAS  Google Scholar 

  28. Hoffman, E.P. & Connor, E.M. Discov. Med. 16, 233–239 (2013).

    PubMed  Google Scholar 

  29. Nakamura, K., Hattori, K. & Endo, F. Am. J. Med. Genet. C. Semin. Med. Genet. 157, 63–71 (2011).

    Article  CAS  Google Scholar 

  30. Kulkarni, A. & Wilson, D.M. III. Am. J. Hum. Genet. 82, 539–566 (2008).

    Article  CAS  Google Scholar 

  31. Xu, M. et al. J. Biol. Chem. 287, 39349–39360 (2012).

    Article  CAS  Google Scholar 

  32. Anderson, S.L. & Rubin, B.Y. Biochem. Biophys. Res. Commun. 336, 150–156 (2005).

    Article  CAS  Google Scholar 

  33. Axelrod, F.B. et al. Pediatr. Res. 70, 480–483 (2011).

  34. Hims, M.M. et al. J. Mol. Med. (Berl.) 85, 149–161 (2007).

    Article  CAS  Google Scholar 

  35. Wang, G.S. & Cooper, T.A. Nat. Rev. Genet. 8, 749–761 (2007).

    Article  CAS  Google Scholar 

  36. Boone, N. et al. Hum. Mutat. 33, 530–540 (2012).

    Article  CAS  Google Scholar 

  37. Rymond, B. Nat. Chem. Biol. 3, 533–535 (2007).

    Article  CAS  Google Scholar 

  38. Kazantsev, A.G. & Thompson, L.M. Nat. Rev. Drug Discov. 7, 854–868 (2008).

    Article  CAS  Google Scholar 

  39. Medina, M., Garrido, J.J. & Wandosell, F.G. Front. Mol. Neurosci. 4, 24 (2011).

    Article  CAS  Google Scholar 

  40. Cullen, V. et al. Ann. Neurol. 69, 940–953 (2011).

    Article  CAS  Google Scholar 

  41. Appelqvist, H., Wäster, P., Kågedal, K. & Öllingerm, K. J. Mol. Cell Biol. 5, 214–226 (2013).

    Article  CAS  Google Scholar 

  42. Kleta, R. & Gahl, W.A. Expert Opin. Pharmacother. 5, 2255–2262 (2004).

    Article  CAS  Google Scholar 

  43. Tuchman, M. et al. Pediatr. Res. 64, 213–217 (2008).

    Article  CAS  Google Scholar 

  44. Huang, R. et al. Sci. Transl. Med. 3, 80ps16 (2011).

    Article  Google Scholar 

Download references

Acknowledgements

P.J.B. is also a Program Director in the Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.

Author information

Authors and Affiliations

  1. Philip J. Brooks and Steve Groft are at the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Bethesda, Maryland, USA.,

    Philip J Brooks & Steve Groft

  2. Danilo A. Tagle is at the Office of Special Initiatives, Office of the Director, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Bethesda, Maryland, USA.,

    Danilo A Tagle

Authors
  1. Philip J Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danilo A Tagle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steve Groft
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip J Brooks.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brooks, P., Tagle, D. & Groft, S. Expanding rare disease drug trials based on shared molecular etiology. Nat Biotechnol 32, 515–518 (2014). https://doi.org/10.1038/nbt.2924

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2924

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing